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Congenital cytomegalovirus infection (CMV) is a leading non-genetic cause of 
sensorineural hearing loss worldwide. The birth prevalence of congenital CMV 
infection correlates positively with the level of CMV seroimmunity in the adult 
population. In addition, women infected with Human Immunodeficiency Virus (HIV) 
constitute a special at risk subpopulation for the intrauterine transmission of CMV. 
Despite a high prevalence of both HIV and CMV, the birth prevalence of congenital 
CMV infection has not been assessed in sub-Saharan Africa. 
Purpose 
The purpose of the study was to determine the birth prevalence of congenital CMV 
infection among HIV-exposed newborns born in a public sector hospital in the 
Western Cape in 2012, during the era of prenatal antiretroviral therapy. 
Objectives 
The objectives of this study were:  
 To determine the prevalence of congenital CMV infection among HIV-
exposed newborns; 
 To assess the predictors of congenital CMV infection transmission among 
HIV-infected women; and 
 To inform the design of an analytic study to determine if newborn CMV 
screening should be implemented in this population.   
Study design 




The study was conducted at Mowbray Maternity Hospital (MMH), which serves the 
Cape Town Metropole area. 
Study population 
The study population comprised infants born to HIV-infected mothers delivering at 
MMH. 
Study sample 
Non-probability convenience sampling was used to enroll 750 newborns. 
Methods 
HIV-infected mothers were recruited in the immediate postnatal period at a referral 
maternity hospital between April and October 2012. Maternal and infant clinical 
data and newborn oral swabs (saliva) were collected. Saliva was assayed by real-
time PCR for CMV. Data were analysed using univariate and multivariate logistic 
regression analyses to determine specific demographic, maternal and newborn 
characteristics associated with congenital CMV infection.   
Results  
CMV was detected in 22/748 newborn oral swabs (2.9%; 95% Confidence Interval 
(CI), 1. 9%-4.4%). Maternal CD4 count less than 200 cells/μL during pregnancy 
was independently associated with congenital CMV infection (adjusted Odds Ratio 
(aOR) 2.9; 95% CI, 1.2-7.3). A negative correlation between CMV viral load in 
saliva and maternal CD4 count was observed (r = -0.495, n = 22, p = 0.019). 
Conclusions 
The birth prevalence of congenital CMV infection was high despite prenatal ARV 
prophylaxis, and was associated with advanced maternal immunosuppression.
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Chapter One: Introduction 
This chapter presents a concise background of the research problem in order to 
contextualize the research aims. It also details the format of the dissertation. 
Cytomegalovirus (CMV) is a common viral infection of humans, but is “not any the 
less challenging through its ubiquity” (1). The role of CMV in producing morbidity 
and mortality in persons with impaired immunity, such as patients with Acquired 
Immune Deficiency Syndrome (AIDS) and transplant recipients, is widely 
appreciated (2, 3). However, the fact that CMV is also a leading cause of 
congenital infections worldwide and an important cause of sensorineural deafness 
and neurodevelopmental delay is barely recognized (4-7). 
The birth prevalence of congenital CMV infection correlates with the level of CMV 
seroimmunitya in the adult population, and is higher in populations with a high 
prevalence of CMV (8, 9). Not only is the birth prevalence of congenital CMV 
infection higher in women with pre-existing CMV immunity, but such immunity also 
fails to protect against symptoms at birth and sequelae in the infant (10-14). Of 
salient concern, hearing loss occurs in 10%-15% of infected infants (14-16). 
In South Africa, persistent infection with CMV in the antenatal population is nearly 
universal (17). In addition, the maternal HIV seroprevalence is among the highest 
in the world, with 30% of antenatal clinic attendees on average seropositive for HIV 
(18). Available data indicate that HIV-infected women constitute a special at risk 
subpopulation for the intrauterine transmission of CMV (19-21). Despite a high 
prevalence of both HIV and CMV in sub-Saharan Africa (22, 23), the birth 
                                            






prevalence of congenital CMV infection has not been assessed in a large sample 
of HIV-exposed newborns in this region. In addition, several factors may influence 
the transmission risk of congenital CMV infection in HIV-infected women, 
particularly the use of antiretroviral therapy (ART)b and maternal immune status as 
measured by CD4 cell counts (20), although these have not been systematically 
assessed in such women. 
In summary, congenital CMV infection and its associated sequelae is a well 
described problem affecting young children in upper income countries, however 
there is sparse data from high HIV prevalence settings where the burden of 
infection and disease is likely to be substantial. As such, the purpose of this study 
was to assess the birth prevalence of congenital CMV infection among HIV-
exposed newborns born in a public sector hospital in the Western Cape during the 
era of prenatal antiretroviral therapyc in 2012. The secondary objectives were to 
investigate the predictors of congenital CMV transmission among HIV-infected 
women, as well as to inform the design of an analytic study to determine if HIV 
exposed infants should be considered for newborn CMV screening in this 
population.  
Chapter One presents a concise background of the research problem in order to 
contextualize the research aims. In Chapter Two a literature review is presented, 
describing the global epidemiology of congenital CMV infection and paucity of 
African data. This is followed by the journal article manuscript in Chapter Three. 
Chapter Four then provides additional results from analyses undertaken on the 
dataset that were not included in the journal article, as well a systematic discussion 
of the study limitations and additional recommendations. Next, Part E contains all 
                                            
b ART encompasses monodrug, dual-drug as well as triple antiretroviral therapy (HAART) used in 
HIV-infected pregnant women for the prevention of mother to child transmission (PMTCT) of HIV. 





appendices, namely the research protocol, University of KwaZulu-Natal (UKZN) 
research ethics approval, acknowledgement of registration for the degree, 
acknowledgement of author roles and contributions, and the instructions to authors 
for the Clinical Infectious Diseases Journal. Lastly, the bibliography for all chapters 






Chapter Two: Literature review 
This chapter begins with a basic background of key aspects of the virology and 
immunology of CMV, together with a brief overview of congenital CMV infection. 
This background information will set the scene for a discussion of the global 
epidemiology and disease burden of congenital CMV infection, which will serve to 
underscore the importance of congenital CMV infection in high seroprevalence 
settingsd as well as in HIV infected women. Next, approaches to preventing the 
burden of congenital CMV infection will be examined with emphasis on the 
challenge posed by maternal non-primary infectione. Finally, an introduction to the 
laboratory diagnosis of congenital CMV infection will be provided, focusing on the 
latest technologies. The chapter will close with a summary of the literature review 
that contextualizes congenital CMV infection as an important cause of hearing loss 
worldwide, and underscores the need for research in South Africa. 
Data for the literature review were identified by searching PubMed to identify full-
length articles as well as abstracts published in English between January 1, 1980 
and June 30, 2014. The following search terms were used: congenital 
cytomegalovirus AND (HIV OR epidemiology OR risk factors OR diagnosis). This 
search gave 1174 results, and after review of titles, 160 abstracts remained. After 
review of the 1174 titles and abstracts, the full text of the 40 relevant articles were 
reviewed. Appropriate citations from these articles were also reviewed. Relevant 
                                            
d These refer to populations where > 90% of the adult population have had past infection with CMV 
and are thus persistently infected and CMV seropositive. Such populations are typically present in 
low and middle income countries. 
e This refers to active CMV infection in persons who are already CMV seropositive as a result of 
past infection with CMV. This may occur as the result of reactivation of latent (endogenous) virus or 





textbook sections on congenital CMV infection were also read for background 
information and a general overview. 
2.1   Background 
CMV belongs to the herpesviridae family of viruses which it shares with herpes 
simplex virus and varicella zoster virus, the causative agents of cold sores and 
chickenpox, respectively (24). Unlike these viruses, infection with CMV is usually 
asymptomatic in healthy individuals (25) which possibly accounts for the low 
awareness of the existence or importance of this pathogen globally (6, 26, 27). 
A common feature of all herpesviral infections is the establishment of a lifelong or 
persistent virus infection following primary infectionf (24). In general, viral infections 
may assume different patterns of persistence within an individual, mainly those of 
latency and chronic infection. In chronic infections such as HIV and Hepatitis B 
Virus (HBV), there is continuous viral production throughout the period of infection, 
which may be detected at any time in the blood or body fluids of infected 
individuals. In comparison, upon primary infection with CMV, there is an initial 
period of active virus production for a few months followed by the establishment of 
latency during which the virus remains dormantg in cells of the monocyte-
macrophage lineage, as well as the immuneprivileged sites of the kidney, 
mammary and salivary glands (24). Reactivation from latency and virus production 
only occurs periodically with virus shedding in blood (viraemia), urine (viruria), 
breast milk, saliva and genital tract secretions (24, 28). As in primary infection, 
such virus excretion is usually of little clinical consequence in healthy persons but 
instead serves as a mode of virus transmission through close contact, 
                                            
f The initial or first time a seronegative person is infected with CMV. 






breastfeeding, sexual contact, and less commonly by blood and organ donation 
(29-31). 
Following primary infection with CMV, an individual mounts an immunological 
response to the virus within weeks to months. The antibody and T cell immune 
response to the virus serve as markers of infection even during periods of absent 
virus excretion (latency). The antibody response detectable in blood is the easily 
measurable component of the immune response and its presence or absence is 
termed seropositivity (seroimmunity) or seronegativity, respectively. The 
appearance of antibodies in the blood of a seronegative person is known as 
seroconversion.h At a population level, the proportion of seropositive individuals is 
termed seroprevalence. 
Despite the presence of a robust immune response to CMV characterized by high 
levels of antibodies and around 10% of the total peripheral T cell compartment 
dedicated to CMV in healthy individuals, CMV is still able to reactivate from latency 
(32, 33). It is thought however that pre-existing immunity serves to limits the 
magnitude and duration of reactivation in healthy individuals. The T cells in 
particular play a crucial role in keeping the virus in a quiescent state for most of its 
period in the host, as well as in preventing uncontrolled replication of the virus 
during periods of active infectioni (32, 34). The importance of intact T cell 
immunosurveillance is evidenced by the production of clinical CMV disease in 
immunocompromised individuals, notably persons with advanced HIV and 
transplant recipients (2, 3, 35). As the developing foetus also has a lower capacity 
                                            
h Transition of a seronegative person to being seropositive. 





for immunoprotection (36), it represents an additional vulnerable host for CMV 
infection and disease (37). 
2.1.1  Congenital CMV infection 
Infection with CMV in utero is known as congenital CMV infection, and is 
distinguished from CMV acquired during birth and postnatally which are termed 
perinatal and postnatal CMV infection respectively. Transplacental transmission of 
CMV leading to congenital infection may occur at any stage of pregnancy, and is 
thought to follow CMV viraemia produced during active CMV infection in the 
mother (38, 39). Apart from reactivation of endogenous virus, CMV seropositive 
mothers can be re-infected with new strains (genotypes) of CMV (40). Reactivation 
of CMV and re-infection with different strains are known as non-primary CMV 
infection, and are differentiated from primary infection on the basis that the former 
occurs in persons with pre-existing immunity. Virus strains are told apart by 
molecular sequencing, which has in recent years revealed a very high diversity of 
CMV within and between individuals (41, 42). These insights suggest a role for 
different virus genotypes in CMV transmission and possibly disease (43). As new 
CMV strains can evade an individual’s pre-existing T cell repertoire (33, 44), re-
infection events may produce higher levels of viraemia in the early stages of 
infection compared with reactivation of latent virus strains. CMV re-infection may 
therefore have implications for transplacental virus transmission in pregnant 
women (45, 46).  
Intrauterine infection leads to symptoms at birth in around 10% of infected infants 
(16). Owing to the broad tissue tropism of CMV, the clinical spectrum of 
symptomatic congenital CMV infection is wide (Table 1), ranging from isolated 
disease through a variable combination of symptoms to disseminated life-





infections are clinically silent in the newborn period, around 10-15% of these 
asymptomatic newborns are at risk of permanent neurological sequelae, the 
majority of which are detectable in the first two years of life (14-16, 48). Overall 
sensorineural hearing loss is the most frequently occurring sequelae of congenital 
CMV infection (16). 
Table 1. Spectrum of clinical outcomes following congenital CMV infection, 
according to type of clinical presentation at birth asymptomatic versus 
symptomatic. 
    Asymptomatic Symptomatic 
     
Proportion of infected infants   90% 10% 
Newborn signs and symptoms    
 
Transient manifestations  
 
Jaundice, hepatosplenomegaly, 
petechial or purpuric rash 
 
Acute CNS manifestations  
 
Microcephaly, seizures, poor 
feeding, lethargy, hypotonia 
 
Laboratory findings  
 
Anaemia (Hb < 11g/dL), raised 
ALT (> 80 IU/L), direct bilirubin > 
2g/dL, thrombocytopenia (< 100 
000/mm3), elevated CSF protein 
or lymphocytes  
Risk of permanent sequelae  14% 40-58% 
Long term sequelae    
 Sensory           Sensorineural hearing loss (uni- or bilateral) 
 Cognitive   Intellectual disability, attention deficit disorder 
  Motor     Spastic diplegia, seizure disorder 
Abbreviations: CNS, central nervous system; Hb, haemoglobin; ALT, alanine 
transaminase; CSF, cerebrospinal fluid. 





2.2 Epidemiology and disease burden of congenital CMV infection 
CMV is a ubiquitous viral infection of humans. Although CMV has a global 
distribution, substantial differences exist in the proportion of seropositive adults 
within and between populations owing to varying rates of CMV acquisition, leading 
to the recognition of low and high CMV seroprevalence settings (49). The rate of 
CMV acquisition in a population increases with age, and correlates inversely with 
socio-economic status and levels of public health standards (24, 49). Therefore, in 
industrialized countries, where primary infection occurs frequently later in life 
(adolescence and adulthood), 50-70% of women of childbearing age are CMV 
seropositive (50). These are considered low seroprevalence settings. In 
comparison, in low and middle income countries, including South Africa, where 
breastfeeding as well conditions of overcrowding are common, CMV infection 
occurs rapidly in infancy and childhood, with the majority of adult women 
seropositive for CMV (17, 49). 
2.2.1 Birth prevalence of congenital CMV infection 
As with the seroprevalence of CMV, the birth prevalence of congenital CMV 
infection exhibits substantial worldwide variation (Table 2), with rates overall of 0.6-
0.7% in industrialized (low seroprevalence) settings compared with 1-5% in low 
and middle income (high seroprevalence) settings (8, 9, 51-53). Kenneson et al. 
tested the hypothesis that the birth prevalence of congenital CMV infection is linked 
to maternal seroprevalence by performing linear regression analysis of 20 study 
populations (8). They found an increase in the birth prevalence of congenital CMV 
infection of 2.6 per 1000 live births for every 10% increase in maternal 
seroprevalence level (Figure 1). In addition, maternal seroprevalence explained 





Table 2. Birth prevalence of congenital CMV infection based on studies of 
unselected infants identified by culture/PCR of urine/saliva. 
  Country Birth years Sample size 
Birth prevalence 
(%) (95% CI) 
Upper income 
countries                                                                                                                                                  
(0.2-1%)     
 Austria 1993 3/1693 0.2 (0.1-0.5) 
 Canada 1973-1976 64/15212 0.4 (0.3-0.5) 
 Denmark 1974-1977 12/3060 0.4 (0.2-0.7) 
 Finland 1972 3/148 2.0 (0.1-5.8) 
 Italy 1994-1995 6/1268 0.5 (0.2-1.0) 
 Japan 1997-2002 37/11938 0.3 (0.2-0.4) 
 Korea 1989-1991 6/514 1.2 (0.6-2.5) 
 Sweden 1978-1986 76/16474 0.5 (0.4-0.6) 
 Slovenia  4/2841 0.1 (0.1-0.4) 
 UK 1979-1982 42/14200 0.3 (0.2-0.4) 
 US-AL 1980-1990 52/9892 0.5 (0.4-0.7)   215/17163 1.2 (1.1-1.4) 
Low and middle 
income                                                                                                                                 
countries                                                                                                                                                              
(1-2%)     
 Chile  1989-1994 12/658 1.8 (1.0-3.2) 
 China pre-1996 18/1000 1.8 (1.1-2.8) 
 Brazil 2003-2009 121/12195 1.0 (0.8-1.2) 
 Mexico 2001 5/560 0.9 (0.4-2.1) 
 Panama 2003-2004 2/317 0.6 (0.2-2.5) 
 India  9/423 2.1 (1.1-4.0) 
Sub-Saharan Africa                                                                                                                                                          
(>2%)     
 Gambia pre-1991* 25/184 13.6 (9.4-19.0) 
 Gambia 2002-2005§ 40/741 5.4 (4.0-7.3) 
 Ivory Coast pre-1978 28/2032 1.4 (1.0-2.0) 
 Nigeria 2013 10/275 3.6 (1.8-6.6) 
     
* Live born infants recruited from rural and urban Gambia. 
§ Conducted in a well-baby nursery. 





Indeed, there has been a growing appreciation in recent years of the contribution of 
non-primary maternal CMV to the incidence of congenital CMV infection (8, 13, 14, 
54). Wang et al. recently estimated the proportion of congenital CMV infection that 
was due to primary versus non-primary maternal infection during the period 1988-
1994 in the United States (US), where the annual incidence of congenital CMV 
infection is in excess of 30 000 cases (54). Using population based data on the 
seroprevalence of CMV and the rates of primary infection in pregnancy, they 
estimated that three-quarters of congenital CMV infections in the US are due to 
non-primary maternal infection, with substantial variation in the attributable fraction 
by race/ethnicity and age. 
 
Figure 1. Linear regression showing association between maternal CMV 
seroprevalence and congenital CMV infection birth prevalence. 
(Source: Kenneson 2007, (8)) 
The contribution of non-primary maternal infection to the majority of congenital 
CMV infections appears paradoxical given that maternal immunity offers 
considerable protection against congenital CMV infection at the individual level (14, 
55). In women with pre-existing immunity (seropositive or seroimmune women), the 
risk of vertical transmission to the foetus is 1-2%, compared with 30-50% in women 





congenital CMV infection birth prevalence at the population level depends not only 
on the individual transmission risk, but also the size of the at-risk population. All 
women with prior CMV infection are at risk, whereas only a fraction of seronegative 
women are infected with CMV during pregnancy and therefore at risk of 
transmitting the virus to their infants. 
The following hypothetical scenario illustrates the role of non-primary maternal 
CMV in driving the birth prevalence of congenital CMV infection as a population 
level phenomenon. In seronegative women of upper income settings, the risk of 
primary CMV infection in pregnancy is 1-7% (56, 57). Assuming a 2% risk of 
primary infection and 35% risk of vertical transmission upon primary infection, the 
combined probability of congenital CMV infection in seronegative women is 0.7% 
(7 per 1000 deliveries). In seropositive women on the other hand, the frequency of 
CMV transmission is 1-2% (8), leading to 10 to 20 vertical infections per 1000 
deliveries. Based on these assumptions, if the CMV seroprevalence in a high 
income population were 50% with a 1% transmission risk in seropositive women, 
the birth prevalence of congenital CMV infection would be around 8.5 per 1000 
deliveries, with 5 infections (59%) or nearly two-thirds attributable to non-primary 
maternal infection. If the seroprevalence in a high income population increased to 
70%, the birth prevalence of congenital CMV infection would be 9.1 per 1000 
deliveries, with 7 infections (77%) attributable to non-primary maternal infection. 
2.2.2 Congenital CMV disease burden 
Congenital CMV infection is a leading cause of childhood hearing loss and 
important cause of mental impairment in high income countries. In the US, 
congenital CMV infection accounts for a fifth to a quarter of cases of hearing loss at 







(Source: Morton 2006, (7)) 
 
Despite a higher birth prevalence of congenital CMV infection in highly seropositive 
populations, the findings of earlier studies of congenital CMV infection among 
infants of women with pre-existing immunity led to a dogma that ‘maternal 
immunity is protective against congenital CMV disease’ (58-60). Stagno et al. 
studied the effects of maternal primary versus non-primary CMV on symptomatic 
disease at birth in the 1970s and 1980s (59). Of the 32 cases of congenital CMV 
infection studied, an equal proportion were due to maternal primary infection and 
non-primary infection, however clinically apparent disease was more common in 
the primary infection group. The authors pooled the data with cases of congenital 
CMV infection identified at other prenatal clinics, and concluded that “congenital 
cytomegalovirus infection resulting from primary maternal infection is more likely to 
be serious than that resulting from recurrent infection” (59). Fowler et al. 






subsequently reported on a cohort of 197 newborns with congenital CMV infection 
born in the US between 1972 and 1990, 125 of whom were born to women with a 
primary infection and 64 of whom were born to women with non-primary infection 
(60). They found that the frequency of one or more sequelae was 25% in the 
primary infection group of infants compared with 8% in the non-primary infection 
group. In addition, mental impairment, bilateral hearing loss and multiple sequelae 
were restricted to the primary infection group. Only a slightly lower proportion of 
infants (83% vs 94%) were identified by screening (versus referral) in the primary 
infection group compared with the non-primary infection group. They concluded 
that “pre-existing maternal antibody to CMV protects the foetus and lessens the 
severity of the sequelae of congenital CMV infection” (60). 
The prevailing view among public health officials has therefore long been that 
congenital CMV infections in seropositive women are mild or inconsequential. 
Given that there is no active screening for congenital CMV infection in most parts 
of the world, most infants are subclinically infected and the symptoms of CMV 
infection in the newborn are non-specific, such a dogma would be difficult to 
disprove in the absence of systematic studies. This has perpetuated a focus on 
strategies that target primary CMV infection in high income countries, and has led 
to continued inattention to congenital CMV infection in low and middle income 
countries. 
In recent decades there has been a growing body of evidence to counter this view 
(11, 13, 14, 61). Ahlfors et al. documented the findings from a prospective long 
term study of 76 infants with congenital CMV infection in Sweden identified by 
population screening of 16 474 newborns between 1977-1985 (61). Of the 80% 
(62/76) of infected newborns in whom type of maternal infection was determined, 





non-primary infection. At seven years of follow up the frequency of neurological 
sequelae was 18% (5/27) in the primary infection group and 26% (6/23) in the non-
primary infection group. Furthermore, a pooled analysis of data from this Swedish 
study combined with a large prospective study of childhood outcomesj in the United 
Kingdom was recently reported by Townsend et al. (Table 3) (13). The authors 
stated that their analysis “highlights the contribution of non-primary maternal 
infection to the burden of congenital CMV disease in childhood, even in countries 
where maternal seroprevalence is relatively low” (13). 
Table 3. Frequency of congenital CMV infection outcomes by type of 




infection at birth   
Moderate/severe 
outcomes 
 no. n %  no. n % 
Type of maternal infection        
        Primary 8 82 9,8  5 73 6,9 
        Non-primary 6 45 13,3  9 39 23,1 
        Not known 5 49 10,2  2 42 4,8 
Total 19 176 10,8  16 154 10,4 
                
Abbreviations: no., number with outcome; n, number of infants with congenital 
CMV infection in that category. 
(Source: Adapted from Townsend 2013, (13)) 
In the US, Ross et al. examined hearing outcomes in a cohort of 300 infants with 
congenital CMV infection, identified by newborn virologic screening, by type of 
maternal infection (11). They documented similar rates of hearing loss of 10% and 
11% in infants born to women with non-primary and primary infection, respectively. 
Although progressive and severe/profound hearing loss was more common in the 
                                            
j Assessments included neurologic, audiologic, and ophthalmologic status and/or development at 





primary infection group, the occurrence of bilateral and high frequency hearing loss 
was not different between the two groups. In support of these findings, de Vries et 
al. recently conducted the first meta-analysis of hearing loss by type of maternal 
infection pooling data from seven prospective studies that identified congenital 
CMV infection by screening of newborns. The pooled estimate of hearing loss 
among infants with congenital CMV infection was 13% (50/385, 95% (Confidence 
Interval (CI) 10%–16%) in the primary infection group and 11% (28/253; 95% CI, 
7%–15%) in the non-primary infection group. Of note, these data are consistent 
with recent findings from large newborn CMV screening studies in India and Brazil 
where maternal CMV seropositivity is nearly universal (12). In Brazil, 9.8% (95% 
CI, 5.1-16.7%) of congenital CMV infected infants developed hearing loss (12), 
whereas unilateral or bilateral sensorineural hearing loss (SNHL) was observed in 
2/20 (10%) children with congenital CMV infection identified between 2010 and 
2012 in New Delhi, India (personal communication, Dr Suresh B Boppana). 
Apart from the type of maternal infection, the frequency of congenital CMV 
infection sequelae has also been examined in relation to the type of newborn 
infection, symptomatic versus asymptomatic. Townsend et al. in their pooled 
analysis of data from the United Kingdom (UK) and Sweden reported that 42% of 
symptomatic (8/19) compared with 14% (19/135) of asymptomatic infants 
developed sequelae (13). In a recent systematic review of studies which included 
populations of low socioeconomic status and avoided studies with an 
overrepresentation of maternal primary infection, Dollard et al. showed that the 
overall prevalence of symptomatic infectionk was 13%, with a 40-58% risk of 
                                            
k Clinical indications of CMV infection in newborns is known as cytomegalovirus inclusion disease 
and was defined as the presence of one or more of the following symptoms: petechiae, jaundice 
with associated hyperbilirubinaemia, hepatosplenomegaly, thrombocytopaenia, chorioretinitis, 






sequelael in symptomatic infants and a 13% risk of sequelae in asymptomatic 
infants (16). Owing to the preponderance of asymptomatic congenital CMV 
infections and the notable frequency of sequelae in this group, Dollard et al. 
estimated that asymptomatic congenital CMV infection contributes a greater 
burden of cases of permanent sequelae as compared with symptomatic congenital 
CMV infection (Dollard, Grosse et al. 2007) (Table 4). 
Table 4. Estimates of long-term sequelae in infants with congenital CMV 
infection according to type of infant infection. 
  Symptomatic  Asymptomatic 
Number of infants 127 (12.7%)  873 (87.3%) 
Deaths 5  0 
Survivors 122  873 
Number with permanent sequelae 50-70 (40-58%)  118 (13.5%) 
Conclusion 17-20% of the 1000 infected infants will 
have permanent sequelae; 1/3 from the 
symptomatic group and 2/3 from the 
asymptomatic group 
(Source: Dollard 2007, (16)) 
 
2.2.3  Role of HIV in congenital CMV infection birth prevalence 
Studies conducted in Europe and the Americas suggest an increased risk of 
intrauterine CMV transmission in mothers infected with both HIV and CMV (Table 
5) (19-21). By impairing cellular immunity, maternal HIV may increase the 
frequency or magnitude of CMV reactivation/re-infection in the mother, thus 
predisposing to intrauterine transmission of CMV. HIV infection of the foetus may 
                                            





also increase its susceptibility to CMV infection in utero. As HIV infected mothers 
are not a homogenous population, the risk of congenital CMV infection is not 
evenly distributed among these women. Indeed, the birth prevalence among 
infants born to HIV-infected women has been shown to vary according to maternal 
characteristics such as CD4 count, antiretroviral therapy (ART) use and infant HIV 
infection status. Infant HIV infection, as well as maternal HIV stage, CD4 count, 
and ART/highly active antiretroviral therapy (HAART)m use may serve as markers 
of maternal immune status during pregnancy and therefore of the risk for 
congenital CMV infection. 
Among infants infected with HIV, the birth prevalence of congenital CMV infection 
ranges from 4.3% to 29% (19, 20). In a retrospective case control study of 
congenital CMV infection and maternal HIV in a Thai clinical trial of zidovudine 
prophylaxis, infants with in utero HIV were found to have an eight times increased 
odds of congenital CMV infection compared with HIV exposed but uninfected 
controls (62), suggesting that congenital CMV infection was a risk factor for 
perinatal HIV in the pre-HAART era (or vice versa). In contrast, in HIV-exposed but 
uninfected newborns the birth prevalence of congenital CMV infection varies from 
2.2% to 6.3%, with rates at the lower end of the range in post- compared with pre-
HAART era (Table 5) (19, 20).  
Studies in Europe (Table 5) have shown overall a reduction in congenital CMV 
infection birth prevalence over time and with increasing maternal HAART use, 
however rates of congenital CMV infection in HIV exposed infants have persisted 
above those of the general population in these countries (20, 63, 64). Furthermore, 
                                            
m Congenital CMV infection rates in the context of HIV-infected pregnant women span two time 
periods, the era preceding and following the introduction of ART/HAART for the prevention of 
mother-to-child-transmission of HIV and restoration of maternal immunity and health. Highly active 






data from France, which represents the largest prospective study of maternal HIV 
and congenital CMV infection, has also demonstrated an association between 
congenital CMV infection and infant HIV infection, as well as maternal CD4 count < 
200 cells/μL close to delivery (20). The French Perinatal Cohort authors also 
examined the impact of duration and type of antiretroviral therapy on congenital 
CMV infection birth prevalence (20). They documented an increased risk of 
congenital CMV infection among mothers initiating ARV therapy in the second 
trimester compared with earlier in pregnancy, and suggested that earlier initiation 
of HAART may protect against CMV reactivation for a longer duration of the 
pregnancy. No difference was found in the risk of congenital CMV transmission by 
type of ARV therapyn. 
 
                                            
n Categories of ARV therapy in this study were HAART, two nucleoside reverse transcriptase 





Table 5. Birth prevalence of congenital CMV infection among HIV exposed infants (HIV-E), including HIV exposed uninfected 








Study population CMV test method 
n 
(infants) 
HIV-E HIV-EU HIV-EI Comment 






HIV infected pregnant women and their 
children enrolled at 96 centers throughout 
France enrolled in EPF cohort. 
urine 
culture/PCR 
4797 111/4797 2.3% 94/4302 2.2% 13/126 10.3% Prevalence of congenital CMV decreased over time with 
increasing use of HAART in the cohort. Congenital CMV 
transmission was associated with delivery period, maternal age, 




Italy     
2000-
2005 
Retrospective survey of cohort of 




303 9/303 3.0% 9/301 3.0%   Congenital CMV infection prevalence was about 10 times higher 
than in the open Italian population (0.2%) but lower than that 
found in a previous Italian study on babies born to HIV infected 
mothers (5.7%). The lower rate of transmission may have been 
due to the reduction of CMV reactivation caused by 
ART/HAART. HIV transmission risk was 0.6%. 
Gabriel 
2005 
Spain   
1987-
2003 
Prospective cohort of consecutive HIV 
infected women and their children. 
urine 
culture 
257 12/257 4.6% 6/234 2.6% 6/23 26% Before 1997 the congenital CMV infection prevalence among 
HIV exposed infants was 9.2 % vs 1.3% in the second period (p 
< 0.01), suggesting an association with study period. In infants 
born to HIV-infected women without zidovudine therapy the 
prevalence was 6.3 % compared with 3.1 % in the group with 






HIV infected women and their children 
recruited from 5 clinical centres in the US 
(P2C2 HIV study group). 
urine 
culture/PCR 
440 11/247 4.5% 9/200 4.5% 2/47 4.3% No significant difference in frequency of congenital CMV 







Los Angeles County referral site for HIV 
infected women and their children. 
urine/ saliva 
culture 
 248 3.6%     Prevalence of congenital CMV infection did not differ over the 
two time periods (1988-1996 vs 1997-2002) by infant HIV 








HIV infected women and their infants. urine 
culture 





Texas    
1997-
2005 
Retrospective cohort of HIV infected 




333 10/333 3% 10/329 3.0% 4  HAART was available for these women during the entire study 
period; HAART use was higher among mothers of CMV 
uninfected infants. CD4 < 200 cells/μL was more common 
among mothers of CMV infected infants. HIV mother-to-child 




Brazil   
1992-
1995 
Consecutive deliveries of low income 
population of CMV seropositive women at 
a University Hospital. Ninety one percent 
were asymptomatic HIV carriers and none 
had late stage HIV infection. 
urine 
culture/PCR 
325   4/150 2.7%   No difference in transmission risk between HIV exposed and 
HIV unexposed infants. Congenital CMV infection birth 
prevalence was 2.9% (5/175) among HIV unexposed infants. 







HIV infected pregnant women and their 
children enrolled in a cohort to study acute 
CMV infection.  
cord blood 
PCR 
   20 6.3% 15 29%  





HIV exposed infants admitted to NICU. urine PCR 395 9/79 11.4%         HIV exposed and HIV unexposed infants were studied. No data 






Abbreviations: EPF, French Perinatal Cohort; ART/HAART, antiretroviral therapy or highly active antiretroviral therapy; USA, United 
States of America; P2C2, Pediatric Pulmonary and Cardiovascular Complications; NICU, neonatal intensive care unit. 
(Source: Adapted from Duryea 2010, (19). Other references referred to in the table are Guibert 2009 (20); Barbi 2006 (64); Gabriel 






In the US, studies from Texas mirror the data from Europe showing an association 
of congenital CMV infection with infant HIV infection, and a reduction in congenital 
CMV infection birth prevalence in post-HAART era (19, 66). Duryea et al. also 
reported an inverse trend between categories of maternal CD4 counts and 
congenital CMV infection prevalence in HIV-exposed uninfected newborns born to 
women using prenatal antiretroviral therapy in the US (19). Data from California, on 
the other hand, show no change in congenital CMV infection birth prevalence 
among infants of HIV infected women from pre- to post HAART era and no 
relationship of congenital CMV transmission with infant HIV infection, although the 
risk of congenital CMV infection in HIV infected women is higher than the general 
population as in studies from other industrialized countries (21, 65). 
In low and middle income countries and high seroprevalence settings, data on 
congenital CMV infection in infants born to HIV-infected women is sparse. In the 
pre-HAART era in Brazil, a study of a selected population of asymptomatic HIV 
infected women and a control group of HIV uninfected women showed no 
association of maternal HIV with congenital CMV infection (67). This study 
suggests that in highly seroimmune populations, maternal HIV may not increase 
the risk for congenital CMV infection above that of the general population if 
maternal health (and by extension, maternal immunity) is intact. Sub-Saharan 
Africa bears the burden of the HIV epidemic with young women of child bearing 
age disproportionately affected (18, 22). However, there is no population based 
data on congenital CMV infection in HIV infected women in this region of the world 
(70). In a recent cross-sectional survey of neonates admitted to a neonatal 
intensive care unit (NICU) in Zambia, Mwaanza et al. demonstrated that maternal 
HIV increased the risk of congenital CMV infection (OR 6.7; 95% CI, 2.1-20.9), 
however no data was reported on maternal CD4 count, ART/HAART use or infant 
HIV status (69). An important drawback of the sample based estimates from this 





represent the burden of CMV in the newborn period. Lanzieri et al. recently 
assessed the burden of congenital CMV infection in infants admitted to NICUs in 
California for the period 2005 to 2010 (71). The authors noted that they were only 
able to identify 5% of the expected number of infants with symptomatic congenital 
CMV infection for that period.  
Overall these data show that maternal ART/HAART use alters the natural history of 
HIV in pregnant women, and may therefore alter the natural history of CMV in the 
mother as well as of congenital CMV infection, in a beneficial way (72). While there 
is a tendency for ART/HAART to lower the transmission of congenital CMV 
infection, most studies show that congenital CMV birth prevalence in HIV exposed 
infants does however remain higher than that of the general population, suggesting 
a residual excess risk even in women on ART/HAART. As none of the studies in 
HIV infected women included a contemporaneous comparison group of HIV 
uninfected women, except small studies of selected populations from Brazil and 
Zambia which did not report on ART/HAART use (67, 69), the impact of maternal 
ART/HAART on congenital CMV infection birth prevalence is inconclusive. With 
increasing rollout of ART/HAART in sub-Saharan Africa in the last decade (73), a 
careful assessment of the risk of congenital CMV infection as well as the burden of 
congenital CMV infection associated sequelae in infants born to HIV infected 
women is warranted. 
A sizeable portion of HIV infections in sub-Saharan Africa are concentrated in 
South Africa and disproportionately affect young women of childbearing age (18). 
In recent years, the South African HIV epidemic has stabilized, with a national adult 
HIV prevalence of 17.3% (95% CI, 16.6%-18.1%) in 2011 (18). In addition, 
strategies to prevent mother-to-child transmission (MTCT) of HIV, especially rollout 
of ART, has resulted in a successful reduction of HIV perinatal transmission rates 





in South Africa remains alarming, ranging from 17% (95% CI, 14.3%-20%) to 
37.4% (95% CI, 35.8%-39%) in 2011 (18). 
With an annual birth cohort in South Africa of approximately one million infants, 
nearly 300 000 infants are born HIV-exposed each year. Assuming a 1%, 3% and 
10% risk of CMV transmission in HIV unexposed (n=700 000), HIV exposed 
uninfected (n=294 000) and HIV infected (n=6 000) newborns respectively, we 
estimated that around 1642 newborns per 100 000 deliveries would be born 
congenitally infected with CMV (annual excess of 6420 infected newborns due to 
maternal HIV) (Table 6). Based on the rates of sequelae from population based 
estimates in the US and UK, approximately 273 infants per 100 000 live born 
infants in South Africa would develop hearing and mental deficits. Furthermore, 
South Africa is likely to have roughly 2.5 times the rate of congenital CMV 
infections and sequelae per capita as compared to the US. 
The above analysis ignored the potential additional risk of congenital CMV infection 
associated sequelae that may occur in HIV exposed infants. In pre-HAART era, 
HIV exposure in the absence of infection was shown to produce immune defects, 
as well as significantly higher rates of childhood morbidity compared with 
unexposed infants (75-77). It is plausible that intrauterine CMV infection may have 
a worse clinical course in HIV exposed but uninfected infants in Africa even in the 
HAART era. As a result, South Africa potentially faces a unique burden of 
congenital CMV infection. In spite of this, there are no reliable data on the birth 
prevalence of congenital CMV infection in general, or in the subpopulation of HIV-







Table 6. Estimated prevalence of congenital CMV infection associated 












Annual birth rate 4 000 000 700 000 294 000 6 000 
Birth prevalence of 
congenital CMV infection  1% 1% 3% 10% 
Annual cases of congenital 
CMV infection  40 000 7000 8820 600 
Total annual cases of 
congenital CMV infection 40 000 16 420 
Total symptomatic at birth 





(40%) 1600 657 
Total asymptomatic at birth 





(14%) 5040 2069 
Total infants with permanent 
sequelae 6640 2726 
 
Per 100 000 
capita§ 2.1 5.2 
Per 100 000 
deliveries 166 273 
            
* Assuming an HIV mother-to-child transmission rate of 2% in South Africa. 
§ Based on a population size in the United States of 316 000 000 persons and in 





2.2.4  Other risk factors for congenital CMV infection 
Apart from maternal non-primary CMV infection driving a higher birth prevalence of 
congenital CMV infection at a population level, and the impact of maternal HIV on 
congenital CMV infection described above, other risk factors for congenital CMV 
infection have also been identified mainly from data in upper income settings. 
These include preterm birth, admission to NICU, Black race, low socioeconomic 
status, young maternal age and CMV re-infection in pregnancy (8, 46). Factors that 
may be relevant to high seroprevalence settings, including South Africa, are 
discussed here. 
2.2.4.1 Young maternal age 
Kenneson et al. summarized data on maternal age and congenital CMV 
transmission from studies in the US and Korea that included data on maternal 
seroprevalence (8). They found an inverse relationship between maternal age and 
birth prevalence of congenital CMV infection. However, after adjusting for maternal 
seroprevalence, the association was no longer significant suggesting that maternal 
seroprevalence was a confounding factor. In a separate large US study that 
included an urban population of predominantly low income, non-white mothers 
delivering at a public hospital between 1980 and 1990, young maternal age (<20 
years) was associated with a nearly five times increased odds (adjusted 
prevalence odds ratio (aPOR) 4.8; 95% CI, 2.6-8.9) of congenital CMV infection, 
compared with mothers aged 30 years and older (78). The authors suggested that 
younger women may have more frequent exposure to CMV through sexual activity, 
or for biological reasons may have poorer control of virus excretion, which places 





2.2.4.2 Maternal CMV re-infection 
Re-infection with a new strain of CMV during pregnancy may carry a higher risk of 
virus transmission in seropositive women than reactivation of endogenous virus. 
Yamamoto et al. recently conducted a case control study of CMV re-infection in 
Brazil and demonstrated that maternal re-infection during pregnancy was more 
frequent among infants with congenital CMV infection than uninfected control 
newborns (OR 4.4; 95% CI 1.9-10.2) (46). In high seroprevalence settings, the 
number of people shedding virus and accordingly the circulating pool of virus and 
force of infection is greater than in low seroprevalence settings (14), increasing the 
likelihood of a re-infection event occurring during pregnancy. 
2.2.4.3 Preterm birth and NICU admission 
In a highly seroimmune population in Brazil, preterm birth was not associated with 
the birth prevalence of congenital CMV infection. In this study, the prevalence of 
congenital CMV infection was 2.1% (95% CI, 0.8%-4.7%) among a sample of 289 
consecutive born preterm infants, and 1.8% (95% CI, 0.5%-5.7%) among 163 
consecutive born term infants as assessed by urine culture or polymerase chain 
reaction (PCR) (79). Santos et al. also determined the frequency of congenital 
CMV infection among newborns from a NICU in Brazil, and found a prevalence of 
6.2% (20/292) by urine PCR screening (80). A study of selected neonates admitted 
to NICU in Hungary also reported similar congenital CMV infection frequencies of 






2.3 Prevention of the burden of congenital CMV infection associated 
sequelae  
From a theoretical perspective, the disease burden from congenital CMV infection 
could be reduced by intervening at different stages of the natural history of this 
infection. This could be accomplished firstly by preventing in utero transmission of 
the virus (primary prevention). If this fails, steps can be taken to limit the effects of 
the infection in the newborn (secondary prevention).  
Currently, there are no effective biomedical strategies available for the prevention 
of in utero CMV transmission. Boosting of maternal immunity in seronegative 
women with primary infection by the administration of CMV hyperimmune globulin 
(HIG) was recently shown in a randomized controlled trial to be ineffective (82). 
Efforts to develop an anti-CMV vaccine continue, with increasing recognition that to 
reduce the burden of congenital CMV disease an effective vaccine would need to 
induce protective immune responses to protect seronegative women against 
primary CMV infection, as well as to protect seropositive women who already have 
natural immunity to CMV. However, as the immunological correlates of protection 
against CMV transmission in seronegative and seropositive women remain elusive, 
vaccine design is challenging (36). 
In the absence of effective immunisation strategies, the restriction of maternal CMV 
infection relies predominantly on behavioural measures to limit CMV infection 
during pregnancy (primary infection in seronegative women, and re-infection in 
seropositive women) such as frequent handwashing, and possibly safe sexual 
practices (83, 84). However, the effectiveness of these strategies have not been 





Secondary prevention requires the prompt identification of congenital CMV 
infection by virologic screening in the newborn period, coupled with the deployment 
of measures that can ameliorate sequelae in the infected newborn, such as the use 
of antiviral therapyo and regular developmental and auditory assessments (85, 86). 
Because symptoms of congenital CMV infection are non-specific, and the vast 
majority of infections and associated sequelae occur in asymptomatic infants (16), 
a substantial reduction of the disease burden from this infection requires a strategy 
of universal or targeted newborn CMV screening. The cost-effectiveness of 
universal newborn CMV screening is currently debatable and context-specific (87, 
88). While targeted screening approaches generally have greater appeal in 
developing settings, these require the prior identification of subpopulations of 
mothers or infants at increased risk for in utero CMV transmission. 
2.4 Laboratory considerations 
The diagnosis of congenital CMV infection relies on the detection of CMV in clinical 
specimens (urine or saliva) within the first 14 days of postnatal life (89, 90). This 
cut off time period is required to differentiate between infections acquired in utero 
compared with those acquired during passage through the birth canal and 
postnatally (38), as the incubation period from inoculation of the virus to peripheral 
excretion is 2 to 8 weeks (89). The usual laboratory methods for the identification 
of CMV in newborn specimens are growth of whole virus in cell culture, or 
detection of virus DNA by PCR. While most clinical laboratories are experienced in 
congenital CMV infection diagnosis using urine, obtaining urine samples from 
infants is often a difficult task, and may require the use of invasive techniques. 
                                            





In recent years, the use of saliva for congenital CMV infection diagnosis has been 
receiving increasing attention. This is not unintuitive given that the virus itself was 
initially discovered in the salivary glands of infants with disseminated congenital 
CMV disease during post-mortem studies in the 1950s (91). Oral swabs of the 
inner cheeks can be obtained noninvasively and without technical expertise, 
making saliva by far a more practical specimen than urine (90, 92). The virus is 
shed in high concentrations in both urine and saliva, and there is a high agreement 
of virus detection between the two sample types when either culture or PCR are 
used (92-94). 
Saliva screening of congenital CMV infection using a low cost rapid in house real 
time PCR assay was recently evaluated in a multi-centre prospective study of 
34 989 newborns in the USA (90). The authors reported a high sensitivity (100%, 
95% CI 95.8%-100%) and specificity (99.9%, 95% CI 99.9%-100%) of the PCR 
assay compared with culture of saliva, and highlighted the utility of saliva PCR for 
mass newborn screening. As the high cost of PCR using commercial CMV assays 
is often seen as a barrier to newborn screening in low and middle income 
countries, the widespread availability of such cheaper technologies are urgently 
needed to better inform cost-effectiveness analyses. 
2.5 Summary 
Congenital CMV infection is a common cause of congenital infections in all parts of 
the world, with higher birth prevalences observed in high seroprevalence settings. 
Seeing as firstly the transmission risk for congenital CMV infection is higher in 
CMV seropositive compared with CMV seronegative women, secondly most 
women are seropositive for CMV and thirdly, sequelae in seropositive women 
occur at a similar rate to seronegative women, maternal non-primary CMV infection 





contrary to the commonly held view, maternal pre-existing antibody neither protects 
against in utero CMV transmission or disease in infected infants when a population 
perspective is taken. In addition, a substantial burden of damaging neurological 
disease, particularly hearing loss, occurs among infants with no clinical signs at 
birth and who can, therefore, only be identified by newborn virologic screening. 
In the US, congenital CMV infection is the second leading cause of childhood 
hearing loss after genetic defects (7). This highlights the potentially preventable 
burden of hearing loss due to congenital CMV infection in industrialized settings. In 
the absence of early detection of hearing impairment, speech, language, and social 
impairment occur in a significant number of infected children, with an estimated 
annual cost of $1-$2 billion in the US (83). Importantly, even unilateral and milder 
forms of hearing impairment are harmful to cognitive, psychological and socio-
emotional development (95-99). In view of these adverse consequences, early 
hearing impairment detection and intervention (EDHI) is gaining increasing 
recognition as a cost-effective strategy (95). But, childhood disabilities have not 
been regarded as a major public health priority in many parts of the world, and data 
on the burden of childhood hearing loss are scarcely available from low and middle 
income countries (96). In addition, data from developed countries suggest a 
sizeable burden of congenital CMV disease in low and middle income countries 
(13, 14), although there are few studies documenting hearing outcomes associated 
with congenital CMV infection in these settings. With emerging reports from large 
newborn CMV screening studies in Brazil and India confirming a role for congenital 
CMV infection as a significant cause of SNHL in high seroprevalence settings (12), 
studies in Africa are even more pressing.  
Sub-Saharan Africa may have an additional burden (above that resulting from a 
high CMV seroprevalence) of congenital CMV infection due to the high burden of 





CMV infection birth prevalence in African HIV exposed newborns (9, 70). With a 
large proportion of pregnant women living with HIV in South Africa, determining the 






Chapter Three: Journal article manuscript 
This section presents a portable document format version of the journal article that 
was published in the Clinical Infectious Diseases Journal encapsulating the key 
findings from this studyp,q. The manuscript was received by the Journal on 19 
September 2013, accepted on 10 February 2014 and first published online on 23 
February 2014. The article begins with a structured abstract, followed by four major 
sections: background, methods, results and discussion. Author contributions, as 
well as a timeline of the research process and an expanded discussion of the study 
limitations are presented later in Chapter Four. 
                                            
p The article uses American English spelling and the rest of the dissertation uses British English 
spelling. 
q “Congenital cytomegalovirus” and “congenital CMV” in the manuscript refer to intrauterine infection 



































Chapter Four: Additional Results, Discussion, Limitations 
and Recommendations 
This chapter details additional analyses and discussion that is intended to 
supplement the journal article manuscript presented in Chapter Three. First, the 
findings from additional data analyses that were undertaken on the dataset but not 
included in the journal article will be presented. This will be followed by a critical 
review of the potential random and systematic sources of error in this study. The 
chapter will close with suggestions for how the study could have been conducted 
under ideal conditions. 
4.1    Additional Results 
The study sample comprised HIV infected women on different prenatal prophylaxis 
regimens, predominantly HAART and prenatal zidovudine (AZT). Although the risk 
of congenital CMV transmission was not associated with antiretroviral (ARV) 
regimen in this study, further analyses were undertaken for each of the ARV 
subgroups to determine if there were predictors of CMV transmission identifiable 
within these groups. This could provide insight into risk factors for congenital CMV 
infection within treatment subgroups in settings deploying WHO option A for the 
prevention of MTCT of HIV. 
4.1.1  Statistical analysisr 
All statistical analysis was undertaken using SPSS version 21 and Stata/IC 13.0 
statistical packages. The dataset for the whole population was split into two files, 
one for mothers on AZT, and one for mothers on HAART. 
 
                                            





4.1.1.1  Descriptive statistics 
 
Means and standards deviation were computed for each of the continuous 
variables (maternal age, length of ARV prophylaxis, maternal CD4 count, 
gestational age and birth weight) for the AZT and HAART groups, as well as within 
AZT and HAART groups using infant CMV status as a grouping variable. Similarly 
for the categorical variables (length of ARV prophylaxis <120 days, maternal CD4 
count <200, prematurity <37 weeks and infant feeding choice), crosstabulations 
were performed for each prophylaxis group as well as within prophylaxis groups 
according to infant CMV status. 
 
4.1.1.2  Analytical statistics 
 
The AZT and HAART groups were compared on each of the continuous (means) 
and categorical variables (proportions), using the unpaired t test and Chi square 
test respectively. All other analyses were intrasubgroup. The Mann-Whitney U test 
was used to compare the distribution of the continuous variables in CMV infected 
versus uninfected infants within each of the prophylaxis groups. The Chi square or 
Fisher’s exact tests were used to test the statistical significance of the association 
between each of the categorical variables and congenital CMV infection within 
each of the prophylaxis groups. Bivariable logistic regression was used to compute 
the odds ratios with confidence intervals for the association of each continuous and 
categorical variable with congenital CMV infection. Finally, multivariable logistic 
regression was done to test the association of multiple prognostic factors with 
congenital CMV infection. 
 
4.1.2  Results 
 





of MTCT of HIV, while 390 mothers were on HAART. Maternal CD4 count, length 
of ARV prophylaxis and birth weight were significantly different between the two 
groups (Table 7), with length of ARV prophylaxis <120 days more common in the 
prenatal AZT group and maternal CD4 count <200 more common in the HAART 
group. 
In the AZT group, length of ARV prophylaxis, gestational age and birth weight were 
significantly different between CMV infected and uninfected infants, with a near 
significant association for maternal CD4 count (Table 8). In the multivariable 
logistic regression, birth weight was an independent predictor of congenital CMV 
infection among mothers on prenatal AZT, with length of ARV prophylaxis <120 
days and maternal CD4 count approaching significance (Table 9). In the HAART 
group, none of the variables were associated with congenital CMV infection in 
bivariate (Table 10) or multivariable analyses (Table 11). 
4.1.3  Discussion 
Mothers enrolled into the study were subject to WHO Option A Guidelines for 
prevention of MTCT of HIV, which stratifies antiretroviral therapy regimens 
according to maternal CD4 count. Specifically, women with a favourable 
immunological profile (CD4 >350 cells/μL) were given AZT monotherapy from 12 
weeks gestation, whereas women with a CD4 count <350 cells/μL were placed on 
triple antiretroviral prophylaxis. In this study, there was roughly an equal split of 
women in each of these prophylaxis groups, providing an opportunity for subgroup 
analysis. Although these analyses were not expected to produce robust estimates, 
they could provide early insights into potentially important associations with 
congenital CMV infection in women on antiretrovirals in the African context, given 





The higher frequency of length of ARV prophylaxis <120 days and maternal CD4 
count < 200 cells/μL in the prenatal AZT group and HAART group, respectively 
reflected implementation of WHO Option A Guidelines. The less favourable 
baseline immunological status in mothers in the HAART group which would have 
selected these women for HAART, whereas the shorter duration of ARV use in the 
prenatal AZT group is consistent with the fact that prenatal AZT use was limited to 
pregnancy, whereas HAART use commenced in some mothers prior to pregnancy. 
Despite these differences, the frequency of congenital CMV infection was similar 
between the two groups, with 2.7% (9/328; 95% CI, 1.3%-5.1%) of infants infected 
with congenital CMV in the AZT group compared with 3.1% (12/390; 95% CI, 
1.6%-5.3%) in the HAART group. This is expected as the longer duration of 
HAART coupled with its efficacy would have improved the immunological status of 
mothers in the HAART group possibly to approximate those in the AZT group. 
However, serial CD4 count measurements were not available in pregnancy and 
only a snapshot of mostly pre-ARV maternal immune status was measured in this 
study. 
In each of the subgroups, the expected direction of association with congenital 
CMV infection based on biological plausibility and the existing literature was 
protective (OR <1) for each of the continuous variables, and harmful (OR >1) for 
each of the categorical variables. In the bivariate analyses, the direction of the ORs 
were consistent with those expected in the AZT group, but this was not the case for 
the HAART group. Birth weight was independently associated with congenital CMV 
infection among mothers on prenatal AZT, and there was also a suggestion that 
length of AZT prophylaxis during pregnancy could impact congenital CMV 
transmission. The possible association between duration of maternal prenatal AZT 
and congenital CMV infection suggests that early initiation of AZT in pregnant HIV-
infected women, who do not require combination antiretroviral therapy for their own 





pre-treatment CD4 count also tended to predict intrauterine CMV transmission in 
this group, it is plausible AZT directly affected CD4 cell immunity. Increasing 
duration of maternal AZT could have hastened immunological recovery (100) or 
prevented CD4 cell decline (101), and thereby reduced the frequency of active 
CMV infection during pregnancy. Furthermore, lengthened maternal AZT use could 
have suppressed maternal HIV viral level to a greater extent (102, 103) and 
consequently reduced the risk of CMV transmission by the mechanisms mentioned 
above. In the Thai Perinatal HIV Prevention trial, the rate of in utero HIV 
transmission was 5.1% in mothers using prenatal AZT from 35 weeks gestation in 
comparison to 1.6% in those on prenatal AZT from 28 gestational weeks (104). It is 
therefore also possible that the protective effect of increasing exposure to 
zidovudine may have been due to a reduction in MTCT of HIV. In the group of 






Table 7. Comparison of demographic, maternal and newborn characteristics 















Mean ± SD 
 
 
Maternal age  
 
 
27.8 ± 6.7 
 
 





<0.001 Length of ARV prophylaxis 
(days) 
129 ± 51 
 
594 ± 821 






Gestational age (weeks) 
 
37.5 ± 1.8 
 
37.5 ± 1.7 
 
Birth weight (kg) 
 
3.1 ± 0.6 
 





Length of ARV prophylaxis 
<120 days 
 
Maternal CD4 count <200 
 

























































Table 8. Comparison of demographic, maternal and newborn characteristics 





















Mean ± SD 
  
 
Maternal age  
 
 
29.2 ± 5.3 
 
 








0.01 Length of ARV prophylaxis 
(days) 
85 ± 53.5 
 
130 ± 50 0.98 (0.97-
0.99) 






Gestational age (weeks) 
 
36.6 ± 2.6 
 




Birth weight (kg) 
 
2.6 ± 0.6 
 







Length of ARV prophylaxis 
<120 days 
 
Maternal CD4 count <200 
 

























































































Gestational age 1.2 (0.8-1.7) 
 
0.41 
Maternal CD4 count <200 4.8 (0.8-28.9) 0.09 
 
Length of ARV prophylaxis <120 days 7.8 (0.9 – 66.7) 0.06 
Table 9. Logistic regression analysis to determine risk factors for congenital 





Table 10. Comparison of demographic, maternal and newborn characteristics 





















Mean ± SD 
  
 
Maternal age  
 
 
27.0 ± 3.6 
 
 








0.7 Length of ARV prophylaxis 
(days) 
538 ± 638 
 
596 ± 826 1.0 (0.99-1.0) 






Gestational age (weeks) 
 
37.7 ± 1.0 
 




Birth weight (kg) 
 
3.1 ± 0.5 
 







Length of ARV prophylaxis 
<120 days 
 
Maternal CD4 count <200 
 


































































Table 11. Logistic regression analysis to determine risk factors for 
congenital CMV infection in HIV-exposed infants born to mothers on HAART. 
 
4.1.4  Limitations 
 
In general, an observed epidemiological association may be due to a true causal 
association between the exposure and outcome, error or a variable combination of 
true association and error. Sources of error include random error, bias and 
confounding. In the subgroup analyses presented in this chapter, random error is 
of particular salience. The subgroup analyses lacked an a priori hypothesis and 
were not powered to detect statistically significant associations. Breaking down the 
dataset into smaller subgroups led to small sample sizes and increased 
imprecision of the estimates. It is not known whether the wide confidence intervals 
for the odds ratios are due to the absence of a true association, or the small 
numbers in the subgroups as standard error is inversely related to sample size. 
Lack of stability in the sample based estimates may also have accounted for the 
unexpected associations in the HAART group. The findings of the subgroup 





















Gestational age 1.02 (0.64-1.64) 
 
0.92 
Maternal CD4 count <200 2.2 (0.67-7.3) 0.19 
 
Length of ARV prophylaxis <120 
days 





4.2    Additional discussion 
 
A brief overview of study limitations was provided in the journal article manuscript 
in Chapter Three. This section extends the discussion of the study limitations, with 
a critical examination of random and systematic sources of error and confounding 
as well as the measures to reduce these. Table 12 summarizes the discussion of 
the study limitations.  
4.2.1 Random sampling error 
 
The study sample size was determined in advance, assuming a congenital CMV 
infection birth prevalence of 2% among infants born to HIV infected women, with a 
desired margin of error of 1%. In addition, confidence intervals and p values were 
provided with the sample based measures of association to determine the 
association between different variables at the population level. 
 
4.2.2 Random information error 
 
Random information error could have occurred during the measurement of each of 
the study variables that were already present in the medical records at the time of 
the study. Specifically, there may have been random error in extraction and 
interpretation of data by the research assistant. Training and supervision of the 
research assistant by specialist neonatologists could be expected to reduce this 
source of random error. In addition, random error could have occurred further 
upstream during laboratory and clinical measurement of the variables recorded in 
the medical charts. This is unlikely as validated instruments and established 
procedures are used for clinical measures such as birth weight and gestational 
age. Furthermore, validated sensitive and specific laboratory test platforms are 





procedures. Although these procedures protect against random error, the study 
findings were limited by the fact that data in the medical records were not 
independently verified by repeat measurements, and the accuracy of the extracted 
data was not independently verified by a third investigator. Random error during 
CMV testing was guarded against by the use of two validated CMV assays and 
duplicate PCR testing. Furthermore, all CMV testing were performed by trained 
laboratory personnel. 
4.2.3 Selection bias 
 
The study base comprised all HIV-infected women delivering at MMH during the 
study period. Convenience sampling (restriction of recruitment to weekday working 
hours) introduced the risk of sampling bias. However, the research assistant 
identified all HIV infected women in the postnatal wards each weekday, and it is 
unlikely that weekend deliveries differed systematically from weekday deliveries as 
parturition is an unplanned event. Overall, 90.9% (757/833) of eligible mothers 
were approached for participation in the study and most women (97.4%, 737/757) 
agreed to participate. Given the high coverage of the study base and high 
participation rates, enrolled mothers were likely representative of all HIV-infected 
mothers delivering at MMH during the study period. 
4.2.4 Information bias 
 
Information bias results from a differential accuracy of information between 
comparison groups, in this case between CMV infected and uninfected infants. 
This is unlikely as data on all variables were collected from the same information 
source using standardized data forms.  
The demographic, clinical and newborn data were largely abstracted from existing 
antenatal records collected as part of routine clinical care, reducing the potential for 





blinded to possible study hypotheses. In addition, clinical data for the study were 
collected prior to identification of CMV infected and uninfected infants, virtually 
eliminating the potential for recall or recording bias. 
CMV testing was conducted by investigators at a distant site independent  
of clinical data, thereby eliminating detection or diagnostic bias. A validated saliva 
PCR test was performed by qualified laboratory personnel with confirmatory testing 
using virus culture as a second detection platform. 
4.2.5 Confounders 
 
Apart from chance and bias, the detection of associations in the study or the 
incorrect estimation of effect sizes could have occurred as a result of a differential 
distribution of risk factors in the study base. Relevant confounding variables were 
dealt with in the analysis phase of the study by logistic regression. In addition, 
where appropriate, categorization of continuous variables was avoided. However, 
residual confounding from unmeasured confounders, unknown confounders and 
confounder mismeasurement could not be excluded. 
In particular, maternal HIV viral load and infant HIV infection are possible 
unmeasured mediators or positive confounders of the association we observed 
between maternal CD4 count and congenital CMV transmission. Women with low 
CD4 counts may be more likely to have a high HIV viral load or to transmit HIV to 
their infants. High HIV loads may drive higher CMV levels due to biological 
interaction and thus predispose to congenital CMV infection. Furthermore, a link 
between infant HIV infection and congenital CMV infection has been suggested by 
data from upper income countries (Table 5). Other potential confounding variables 
include maternal education and socioeconomic status, which were not measured in 
this study. 
In the overall study sample, the direction of association of each of the variables of 





with a protective effect estimate noted for each of the continuous variables and  an 
increased risk noted for each of the categorical variables (Tables 1 and 2 in the 
journal article manuscript). This seems to suggest that the study findings were valid 
overall. This study was powered to determine congenital CMV infection birth 
prevalence, and not the association of any predictor variable with congenital CMV 
transmission. Therefore, nonsignificant associations are difficult to interpret and 





Table 12. Threats to internal validity and measures to address these. 
    
Potential source  Measures to reduce Residual source 
Random 
sampling error  
Random sampling 
from study base 
Sample size was calculated in advance to achieve 
precision of 1%. Confidence intervals and p values 





 Measurement of 
study variables in 
medical records 
Established clinical procedures were used and quality 
assurance of laboratory (CD4 count) tests are routine 
practice. 
Repeated measurements for 
research purposes were not 
done. 
  Abstraction of study 
data from medical 
records 
Training and supervision of the research assistant 
was ensured. 
Independent verification of 
abstracted data was not done.  
  Laboratory testing 
of study specimens 
Testing was undertaken by trained personnel using 









Eligible population comprised consecutive deliveries, 
with weekends excluded. Weekend deliveries should 
not differ from weekday deliveries.  
 
  Non-participation 
bias 






 Interviewer bias, 
recall/reporting bias 
and recording bias 
Not applicable as possible study hypotheses were not 
revealed to the research assistant or participants. 
Infant CMV status was not known at time of data 
collection and medical records were the major data 
source. 
 
  Diagnostic 
suspicion bias 
CMV testing was conducted at distant site by blinded 
personnel. 
 
  Laboratory tests An accurate validated saliva PCR test was used. 
Confirmatory testing was done using an established 
test method (virus culture). 
Freezing and storage of 
specimens could have 
affected validity of PCR and 
culture results. 
  Standardized procedure used for infant swab 
collection, with waiting period in breastfeeding 
women. 
Breast milk contamination of 
samples could have generated 
false positive results. 
Confounding   Uneven distribution 
of risk factors in the 
study base 
Multivariable modelling (logistic regression) was used. Residual confounding could 
have occurred due to 
unknown or unmeasured 








4.3   Additional recommendations 
 
If we had an opportunity to repeat the study with the primary objective of obtaining 
a prevalence estimate under the conditions of unlimited resources, a few aspects 
of the study would have been approached differently. 
In order to reduce selection bias and improve external validity, we would have 
extended the working hours of the research assistant to include weekends. This 
would have provided an opportunity to invite all HIV infected women to participate 
in the study. Furthermore, reasons for non-participation and baseline information 
would have been documented on mothers declining participation using a rapid 
questionnaire. This would have allowed for the evaluation of non-participation bias. 
To reduce information bias and improve the breadth of information generated from 
the study, we would have carried out the study with personal identifying information 
and undertook local CMV testing. All data would have been collected as part of 
study procedures and verified against antenatal and neonatal records. We would 
have set up and validated the UAB developed saliva PCR assay in the Virology 
Laboratory at Groote Schuur Hospital. All saliva specimens would have been 
collected in duplicate for confirmatory testing in the US. In addition, a urine 
specimen would have been collected from all infants to compare sensitivity and 
specificity of CMV detection in saliva and urine under local conditions. 
Furthermore, besides using the UAB developed saliva assay, we would have 
repeated all tests using an existing commercial assay to compare the performance 
of the two assays. By running the tests locally, we would have been able to follow 
up all infants with confirmed congenital CMV infection in real time, with a 
systematic assessment of clinical features including newborn hearing screening in 





Finally, to improve the quality of information about predictor variables, it would 
have been preferable to have enrolled mothers at their first antenatal visit and 
collected baseline and serial demographic, clinical, immunological and virologic 
data (HIV and CMV) on enrolled mothers. We would also have assessed infant HIV 
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Table 1a. Study variables according to category 






Maternal Maternal age MOMAGE Continuous Mean, SD Independent 
 
Maternal ARV regimen 
- AZT and NVP in labour only 
- AZT during pregnancy 
- HAART 
- None 
PROPHLY Categorical Proportions Independent 
 Date of initiation of ARV STARTPROP Continuous   
 Maternal CD4 count CD4STAT Continuous Mean, SD Independent 
 Date of CD4 count DATECD4 Continuous   
Infant Infant date of birth DOB Continuous   
 Infant gestational age GESTAGE Continuous Mean, SD Independent 
 Infant birth weight BIRTHWT Continuous Mean, SD Independent 
 Infant feeding choice FEED Categorical Proportions Independent 
 Saliva CMV PCR result SALPCR Categorical Proportion Dependent 
 Saliva CMV viral load SALVL Continuous Geometric 



















DPOSTDEL DATESPEC – DOB Continuous Mean, SD  
Length of ARV 
prophylaxis 
DURARV DOB – DATECD4 Continuous Mean, SD Independent 
Gestational 
age at CD4 
count  
GACD4STAT 
[GESTAGE*7 – (DOB 
– DATECD4)]/7 
Continuous Mean, SD  
Maternal age 
less than 20 
MOMAGELT20 20 years Categorical Proportions Independent 
Birth weight 
less than 2500 
BWLT2500 2500 grams Categorical Proportions Independent 
CD4 count 
less than 200 
CD4LT200 200 cells/uL Categorical Proportions Independent 
Prematurity GALT37 37 weeks Categorical Proportions Independent 
Length of ARV 
prophylaxis 
less than 120 































informed consent sheet will explain the voluntary nature of participation, and that 











































Durban, where I have since completed two semesters of coursework for the MPH. 
During this time, I received the study results from UAB, undertook the data analysis 
and have prepared a manuscript with the potential for peer-review and publication, 
listing both UCT Division of Medical Virology and UKZN Discipline of Public Health 
Medicine as my affiliations. 
All investigators have approved of the use of this data towards my MPH at UKZN. In 
addition, the protocol has been internally reviewed in the Discipline of Public Health 
Medicine for scientific integrity, and the study has been approved by Prof. Mars, 
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Table 13. Timelines of research activities from protocol development to 
manuscript publication. 
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